Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET)

NCT00509899 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT00509899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00509899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET)
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2007
Completion date
February 28, 2017
Enrollment
154 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, polycythemia vera, thrombocytosis